TTNP Key Stats
|Revenue (Quarterly YoY Growth)||78.99%|
|EPS Diluted (TTM)||0.0563|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||9.641M|
|Gross Profit Margin (Quarterly)|
|Profit Margin (Quarterly)||-52.09%|
|Dividend Yield (TTM)||0.00%|
|Payout Ratio (TTM) Pro||Go Pro|
- ILMN Seeks CE Mark For Upgraded Assay - Analyst Blog Zacks Sep 26
- TITAN PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 4
- Titan Pharmaceuticals Announces Submission of FDA Meeting Request Regarding Probuphine Marketwired Sep 4
- The FDA Should Have Approved Probuphine, But They Didn't... So Now What? Aug 16
- Titan Pharmaceuticals' Management Discusses Q2 2013 Results - Earnings Call Transcript Seeking Alpha Aug 15
- TITAN PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 14
- Titan Pharmaceuticals Announces Second Quarter 2013 Financial Results Marketwired Aug 14
- Titan Pharmaceuticals Announces Publication of Phase 3 Probuphine Data in Addiction Marketwired Aug 13
- Titan Pharmaceuticals Schedules Conference Call to Review Second Quarter 2013 Financial Results Marketwired Aug 8
- TITAN PHARMACEUTICALS INC Files SEC form 10-K/A, Annual Report Jul 23
TTNP Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Titan Pharmaceuticals is down 32.38% over the last year vs S&P 500 Total Return up 29.68%, Actelion up 63.10%, and BioDelivery Sciences up 24.76%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for TTNP
Pro Strategies Featuring TTNP
Did Titan Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Titan Pharmaceuticals, Inc., is a biopharmaceutical company developing proprietary therapeutics for the treatment of serious medical disorders.